MAVIK (trandolapril) · AbbVie
MAVIK is FDA-approved to treat 4 conditions (same as TRANDOLAPRIL).
Details
- Status
- Discontinued
- First Approved
- 1996-04-26
- Routes
- ORAL
- Dosage Forms
- TABLET
MAVIK Approval History
What MAVIK Treats
4 indicationsMAVIK is approved for 4 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypertension
- Heart Failure
- Left Ventricular Dysfunction
- Myocardial Infarction
Same approved indications as TRANDOLAPRIL (same active ingredient).
AbbVie's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07547878 RAPID-CKD | 026-271 | Ph 4 | not yet recruiting | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MAVIK FDA Label Details
Indications & Usage
FDA Label (PDF)MAVIK is FDA-approved to treat 4 conditions — same approved indications as TRANDOLAPRIL.
Track MAVIK with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.